Abstract
Endothelin (ET) was discovered in 1988 and is the most potent vasoconstrictive peptide known to date. It exists in three isoforms (ET-1 to ET-3) and acts on two endothelin receptor subtypes, the endothelin-A (ETA)-receptor and the endothelin-B (ETB)-receptor. Endothelin receptor antagonists are novel therapeutics in clinical development for different cardiovascular, cerebrovascular, and renal diseases. Several different structural classes of endothelin receptor antagonists have been discovered within the last decade, starting from peptidic- and peptidomimetic structures to small organic molecules suitable as therapeutics for oral administration. Focussing on the small organic molecules, the different structural classes of ET-receptor antagonists are described with respect to synthesis, structure-activity-relationships, receptor-subtype-selectivity profile, and where possible, intended therapeutic indications.
Keywords: Endothelin Receptor Antagonists, Sitaxsentan, Darusentan, Tezosentan, Myriceric Acid-Derivatives, Pyrrolidine-3-Carboxylic Acids, Tetra-Substituted Pyrimidine
Current Medicinal Chemistry
Title: Endothelin Receptor Antagonists: Structures, Synthesis, Selectivity and Therapeutic Applications
Volume: 9 Issue: 3
Author(s): C. Boss, M. Bolli and T. Weller
Affiliation:
Keywords: Endothelin Receptor Antagonists, Sitaxsentan, Darusentan, Tezosentan, Myriceric Acid-Derivatives, Pyrrolidine-3-Carboxylic Acids, Tetra-Substituted Pyrimidine
Abstract: Endothelin (ET) was discovered in 1988 and is the most potent vasoconstrictive peptide known to date. It exists in three isoforms (ET-1 to ET-3) and acts on two endothelin receptor subtypes, the endothelin-A (ETA)-receptor and the endothelin-B (ETB)-receptor. Endothelin receptor antagonists are novel therapeutics in clinical development for different cardiovascular, cerebrovascular, and renal diseases. Several different structural classes of endothelin receptor antagonists have been discovered within the last decade, starting from peptidic- and peptidomimetic structures to small organic molecules suitable as therapeutics for oral administration. Focussing on the small organic molecules, the different structural classes of ET-receptor antagonists are described with respect to synthesis, structure-activity-relationships, receptor-subtype-selectivity profile, and where possible, intended therapeutic indications.
Export Options
About this article
Cite this article as:
Boss C., Bolli M. and Weller T., Endothelin Receptor Antagonists: Structures, Synthesis, Selectivity and Therapeutic Applications, Current Medicinal Chemistry 2002; 9 (3) . https://dx.doi.org/10.2174/0929867023371139
DOI https://dx.doi.org/10.2174/0929867023371139 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bicyclic 6 + 6 Systems: Advances in the Chemistry of Heterocyclic Compounds Incorporated Pyrimido[1,2-a]Pyrimidine Skeleton
Mini-Reviews in Organic Chemistry Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview
Cardiovascular & Hematological Disorders-Drug Targets The Role of Polyunsaturated Fatty Acids (PUFA) in the Treatment of Dyslipidemias
Current Pharmaceutical Design Electrocardiographic Abnormalities in Thalassemia Patients with Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets The Hormetic Role of Dietary Antioxidants in Free Radical-Related Diseases
Current Pharmaceutical Design Lower Sodium Intake and Renal Protective Effects
Current Hypertension Reviews Novel Carriers for Coenzyme Q10 Delivery
Current Drug Delivery Medicinal Chemistry and Anti-Inflammatory Activity of Nitric Oxide-Releasing NSAI Drugs
Mini-Reviews in Medicinal Chemistry The Role of Statins in the Treatment of Type 2 Diabetes Mellitus: An Update
Current Pharmaceutical Design Treatment of Chronic Hepatitis B: From Research to Clinical Practice Via the Consensus Conferences
Current Pharmaceutical Design Mutations of the Apolipoprotein A5 Gene with Inherited Hypertriglyceridaemia: Review of the Current Literature
Current Medicinal Chemistry Epidemiology and Natural History of Patients with NAFLD
Current Pharmaceutical Design Effects of High Altitude Exposure on Physiology and Pharmacokinetics
Current Drug Metabolism Genetics of Atrial Fibrilation: In Search of Novel Therapeutic Targets
Cardiovascular & Hematological Disorders-Drug Targets Effect of Using Nanoparticle-based Diesel Fuel on Enhancement of Performance and Emissions of Diesel Engines
Nanoscience & Nanotechnology-Asia Recent Developments in Female Hormonal Contraception
Current Women`s Health Reviews Grape Seed Proanthocyanidins Protect N2a Cells against Ischemic Injury via Endoplasmic Reticulum Stress and Mitochondrial-associated Pathways
CNS & Neurological Disorders - Drug Targets Tailored Quinolines Demonstrate Flexibility to Exert Antitumor Effects through Varied Mechanisms-A Medicinal Perspective
Anti-Cancer Agents in Medicinal Chemistry Elongated Internal Carotid Arteries in Patients with Severe Carotid Artery Stenosis
Current Neurovascular Research The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis